Trump's tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks
Leerink Partners analyst David Risinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
David Risinger
since
auto-detected in 21 stories
32 days ago
Trump's tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks
Leerink Partners analyst David Risinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
87 days ago
Leerink upgrades this beaten-down biotech stock, says investors should buy the dip
Analyst David Risinger upgraded shares to outperform. He also raised his price target to $834 from $762.
page 1 of 1